福瑞股份收盘下跌1.82%，滚动市盈率92.47倍，总市值91.73亿元

Group 1 - The core viewpoint of the articles indicates that Furuya Co., Ltd. is experiencing a decline in stock price and has a high PE ratio compared to its industry peers [1][2] - As of June 5, the closing price of Furuya Co., Ltd. was 34.44 yuan, down 1.82%, with a rolling PE ratio of 92.47 times and a total market value of 9.173 billion yuan [1] - The average PE ratio for the medical device industry is 50.97 times, with a median of 36.67 times, placing Furuya Co., Ltd. at the 106th position in the industry ranking [1][2] Group 2 - On June 5, there was a net outflow of 37.6122 million yuan in the main funds for Furuya Co., Ltd., with a total outflow of 102.3071 million yuan over the past five days [1] - The main business of Furuya Co., Ltd. includes the production and sales of drugs in the liver disease field, development and sales of diagnostic equipment, and related medical services, with its primary product being the compound turtle shell soft liver tablets [1] - In the latest quarterly report for Q1 2025, Furuya Co., Ltd. achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, and a net profit of 28.6367 million yuan, a year-on-year decrease of 32.97%, with a sales gross margin of 76.76% [1]